BRAF mutation testing in clinical practice

摘要: Activating mutation of KRAS plays a significant role in the pathogenesis common human malignancies and molecular testing has emerged as an essential biomarker current practice clinical oncology. The presence is generally associated with aggressiveness cancer reduced survival patient. Therapeutically, maximum utility stratifying metastatic colorectal carcinoma lung patients for treatment targeted therapy. Diagnostically, useful workup pancreaticobiliary thyroid cancers, particularly using cytological specimens. In era precision medicine, poised to expand, likely setting combinatorial therapeutic strategy requiring additional its upstream and/or downstream effectors.